Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

People taking Zepbound, or interested in starting, will now have several vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 ...

Eli Lilly & Co has announced a $27-billion expansion of its US manufacturing operations, adding four new sites and creating ...

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...

Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

Eli Lilly has unveiled a $27bn investment in US manufacturing facilities as the pharmaceutical industry prepares for the threat of tariffs and mounts a charm offensive aimed at President Donald ...

Discover Eli Lilly's latest offering of discounted high-dose Zepbound vials, now available for $499 for a four-week supply.

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients ...